Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Pipeline Review, H1 2017

  • ID: 4315540
  • Report
  • 61 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Celgene Corp
  • Forty Seven Inc
  • Surface Oncology Inc
  • Trillium Therapeutics Inc
  • MORE
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Pipeline Review, H1 2017

Summary:

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) pipeline Target constitutes close to 13 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report Leukocyte Surface Antigen CD47 - Pipeline Review, H1 2017, outlays comprehensive information on the Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - CD47 (Cluster of Differentiation 47) or integrin associated protein (IAP) is a transmembrane protein encoded by the CD47 gene. It has a role in both cell adhesions by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. It plays an important role in memory formation and synaptic plasticity in the hippocampus (By similarity). It acts as a receptor for SIRPA. Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and co-stimulates T-cell activation. It plays an important role in membrane transport and/or integrin dependent signal transduction. It prevents premature elimination of red blood cells. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 4 and 2 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Immunology, Infectious Disease and Metabolic Disorders which include indications Solid Tumor, Non-Hodgkin Lymphoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Breast Cancer, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Atherosclerosis, B-Cell Non-Hodgkin Lymphoma, Bacterial Infections, Chronic Lymphocytic Leukemia (CLL), Colorectal Cancer, Cutaneous T-Cell Lymphoma, Diabetic Retinopathy, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Head And Neck Cancer, Hematological Tumor, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Ischemia Reperfusion Injury, Kidney Transplant Rejection, Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Breast Cancer, Mycosis Fungoides, Ovarian Cancer, Pancreatic Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Small-Cell Lung Cancer and T-Cell Lymphomas.

Furthermore, this report also reviews key players involved in Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)
  • The report reviews Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Celgene Corp
  • Forty Seven Inc
  • Surface Oncology Inc
  • Trillium Therapeutics Inc
  • MORE
  1. Introduction
  2. Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Overview
  3. Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Therapeutics Development
  4. Products under Development by Stage of Development
  5. Products under Development by Therapy Area
  6. Products under Development by Indication
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Therapeutics Assessment
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Companies Involved in Therapeutics Development
  14. Aurigene Discovery Technologies Ltd
  15. Celgene Corp
  16. Forty Seven Inc
  17. Surface Oncology Inc
  18. Trillium Therapeutics Inc
  19. Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Drug Profiles
  20. ALX-148 - Drug Profile
  21. Product Description
  22. Mechanism Of Action
  23. R&D Progress
  24. B-6H12 - Drug Profile
  25. Product Description
  26. Mechanism Of Action
  27. R&D Progress
  28. CC-90002 - Drug Profile
  29. Product Description
  30. Mechanism Of Action
  31. R&D Progress
  32. Hu-5F9G4 - Drug Profile
  33. Product Description
  34. Mechanism Of Action
  35. R&D Progress
  36. Monoclonal Antibody to Inhibit CD47 for Cardiovascular Disease, Kidney Transplantation and Oncology - Drug Profile
  37. Product Description
  38. Mechanism Of Action
  39. R&D Progress
  40. Monoclonal Antibody to Inhibit IAP for Diabetic Retinopathy - Drug Profile
  41. Product Description
  42. Mechanism Of Action
  43. R&D Progress
  44. Peptide to Inhibit CD47 for Immuno-Oncology - Drug Profile
  45. Product Description
  46. Mechanism Of Action
  47. R&D Progress
  48. PSTx-23 - Drug Profile
  49. Product Description
  50. Mechanism Of Action
  51. R&D Progress
  52. Small Molecules to Inhibit CD47 for Oncology - Drug Profile
  53. Product Description
  54. Mechanism Of Action
  55. R&D Progress
  56. SRF-231 - Drug Profile
  57. Product Description
  58. Mechanism Of Action
  59. R&D Progress
  60. tigecycline - Drug Profile
  61. Product Description
  62. Mechanism Of Action
  63. R&D Progress
  64. TTI-621 - Drug Profile
  65. Product Description
  66. Mechanism Of Action
  67. R&D Progress
  68. TTI-622 - Drug Profile
  69. Product Description
  70. Mechanism Of Action
  71. R&D Progress
  72. Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Dormant Products
  73. Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Product Development Milestones
  74. Featured News & Press Releases
  75. Jun 07, 2017: Trillium Expands Clinical Trial with TTI-621 to Include Combination with PD-1 Blockade
  76. May 31, 2017: Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at 2017 ASCO Annual Meeting
  77. Apr 10, 2017: Alexo Therapeutics Announces Initiation of Phase 1 Clinical Trial of ALX148 for the Treatment of Advanced Solid Tumors and Lymphoma
  78. Apr 05, 2017: The Leukemia & Lymphoma Society Expands its Innovative Therapy Acceleration Program with a Novel Immunotherapy for Lymphoma Patients
  79. Apr 03, 2017: Trillium Therapeutics Presents TTI-621 Preclinical Data at AACR Annual Meeting and Provides Clinical Update
  80. Mar 31, 2017: Aurigene to Present Data on CD47-SIRPÎ interaction program at the AACR
  81. Feb 24, 2017: Trillium Therapeutics Provides Additional Details on ASCO-SITC Conference Presentation on TTI-621
  82. Feb 15, 2017: Trillium Therapeutics to Present New Data from TTI-621 Phase 1 Trial
  83. Feb 02, 2017: Trillium Therapeutics Provides Update On TTI-621
  84. Feb 02, 2017: Trillium Therapeutics Provides Update On TTI-622
  85. Jan 31, 2017: Trillium Therapeutics Doses First Patient With TTI-621 in Phase 1 Solid Tumor Trial
  86. Dec 15, 2016: Surface Oncology Appoints Robert Ross, MD as Chief Medical Officer
  87. Dec 03, 2016: Trillium Presents Initial Data From Ongoing Study of TTI-621 in Patients With Advanced Hematologic Malignancies at the American Society of Hematology Annual Meeting
  88. Dec 02, 2016: Surface Oncology CD47 Program Demonstrates Promising Anti-Tumor Activity in Hematological Disease Models
  89. Nov 29, 2016: Trillium Therapeutics Announces Conference Call and Webcast on December 5th to Discuss TTI-621 Data Presented at ASH
  90. Appendix
  91. Methodology
  92. Coverage
  93. Secondary Research
  94. Primary Research
  95. Expert Panel Validation
  96. Contact Us
  97. Disclaimer
List of Tables:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Indications, H1
  4. Number of Products under Development by Indications, H1 2017 (Contd..1), H1
  5. Number of Products under Development by Companies, H1
  6. Products under Development by Companies, H1
  7. Products under Development by Companies, H1 2017 (Contd..1), H1
  8. Products under Development by Companies, H1 2017 (Contd..2), H1
  9. Number of Products under Investigation by Universities/Institutes, H1
  10. Products under Investigation by Universities/Institutes, H1
  11. Number of Products by Stage and Mechanism of Actions, H1
  12. Number of Products by Stage and Route of Administration, H1
  13. Number of Products by Stage and Molecule Type, H1
  14. Pipeline by Aurigene Discovery Technologies Ltd, H1
  15. Pipeline by Celgene Corp, H1
  16. Pipeline by Forty Seven Inc, H1
  17. Pipeline by Surface Oncology Inc, H1
  18. Pipeline by Trillium Therapeutics Inc, H1
  19. Dormant Projects, H1
List of Figures:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Top 10 Indications, H1
  4. Number of Products by Stage and Mechanism of Actions, H1
  5. Number of Products by Routes of Administration, H1
  6. Number of Products by Stage and Routes of Administration, H1
  7. Number of Products by Molecule Types, H1
  8. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Aurigene Discovery Technologies Ltd
  • Celgene Corp
  • Forty Seven Inc
  • Surface Oncology Inc
  • Trillium Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll